SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (FR0011049824, ALMDT, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer diagnosis and a global leader in AI-based image analysis and central imaging services for oncology drug development, today announced that it will feature eyonis® LCS at the European Congress of Radiology (ECR) 2026 in Vienna, March 4–6, 2026. The
Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology
